• GE Acquires Strategic Assets from TFS

News

GE Acquires Strategic Assets from TFS

Under a new agreement GE Healthcare is to acquire Thermo Fisher’s HyClone™ cell culture media and sera, and gene modulation and magnetic beads businesses for approximately $1.06 billion.  The acquisition will allow GE to expand its offering of technologies for the discovery and manufacturing of innovative new medicines, vaccines and diagnostics in its growing Life Sciences business. 

The transaction, which is subject to regulatory approvals, is anticipated to close in the first part of 2014. 

John Dineen, President and CEO, GE Healthcare said, “Life Sciences is one of our strongest and fastest-growing business areas, driven by the world’s demand for improved diagnostics and new, safer medicines.  Combining GE’s engineering expertise with our capabilities in life sciences is already bringing great benefits to industry, research and patients.  This deal makes a good business even better and will help us realize our vision of bringing better healthcare to more people at lower cost.”

Kieran Murphy, President and CEO of GE Healthcare’s Life Sciences division said, “We look forward to the HyClone cell culture and other businesses joining the GE family.  They are a great fit with our key areas of focus, and bring exciting new technologies, enhanced manufacturing capabilities as well as a great group of talented people to help grow our business.”

“In addition to providing us with new approaches to drug discovery and biomedical research,” Murphy said, “this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing.  They will benefit immediately from an expanded range of “start-to-finish” technologies that will help them improve product yields and reduce time-to-market. By expanding our production facilities to three continents, we will be able to offer the biopharmaceutical industry greater confidence in the security of supply of cell culture media and sera, a key part of their production process.”

The three acquired businesses generated combined annual revenues of approximately $250 million in 2013.


Digital Edition

Lab Asia Dec 2025

December 2025

Chromatography Articles- Cutting-edge sample preparation tools help laboratories to stay ahead of the curveMass Spectrometry & Spectroscopy Articles- Unlocking the complexity of metabolomics: Pushi...

View all digital editions

Events

Smart Factory Expo 2026

Jan 21 2026 Tokyo, Japan

Nano Tech 2026

Jan 28 2026 Tokyo, Japan

Medical Fair India 2026

Jan 29 2026 New Delhi, India

SLAS 2026

Feb 07 2026 Boston, MA, USA

Asia Pharma Expo/Asia Lab Expo

Feb 12 2026 Dhaka, Bangladesh

View all events